Hyderabad, Telangana, India, April 2026 – Neuland Laboratories Limited has announced the appointment of Saharsh Davuluri as Chief Executive Officer & Managing Director, marking a significant leadership milestone for the global CDMO organization. Having been closely associated with Neuland’s evolution, Saharsh brings deep institutional knowledge along with a strong focus on quality, execution, and customer partnerships.
The company highlighted his instrumental role in building capabilities across complex APIs, peptides, and advanced chemistries, and expressed confidence in his leadership as Neuland advances its vision of shaping a healthier tomorrow.
Saharsh Davuluri has had a long-standing association with Neuland Laboratories Limited, spanning nearly two decades. Prior to his current appointment, he served as Vice Chairman and Managing Director, where he played a critical role in driving strategic growth and strengthening the company’s global CDMO capabilities.
Earlier, he held the position of Joint Managing Director, where he was responsible for overseeing Sales, Marketing, Business Development, and R&D across Neuland’s Generic API, Custom Manufacturing (CMS), and Peptides businesses. His leadership during this period contributed significantly to expanding the company’s scientific and commercial capabilities.
Before joining Neuland, Saharsh worked as an Investment Associate (Carolina Venture Fellow) at Pappas Ventures, gaining exposure to venture investments in the life sciences sector. He also held the role of Area Manager – Sales at Sify Limited, building early experience in business and market development.
He holds an MBA in Finance from UNC Kenan-Flagler Business School, further strengthening his strategic and financial acumen.
About Neuland Laboratories Limited
Neuland Laboratories Limited is a globally recognized Contract Development and Manufacturing Organization (CDMO), founded in 1984, specializing in customized new chemical entity (NCE) development services. The company partners with pharmaceutical and biotechnology firms across the entire product lifecycle, from early-stage development to commercial manufacturing.
With strong capabilities in APIs, peptides, and advanced chemistries, Neuland delivers high-quality, scalable solutions supported by advanced technologies and deep scientific expertise. The organization continues to play a critical role in enabling innovation and supporting global healthcare needs.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
